Tekedia Capital welcomes Exin Therapeutics to our community. Exin Therapeutics is a biotech company that is developing genetic therapies that target neural activity for people suffering from neurological and neuropsychiatric disorders such as epilepsy, debilitating symptoms of autism spectrum disorder, and Parkinson’s disease.
The innovation in Exin Therapeutics is the circuit-level approach it is taking to treat these brain disorders. Largely, instead of trying to restore missing genes, they’re supplementing already existing genes that directly change the neural activity in the brain. A proprietary AI system they invented is assisting them in the development.
For us, this is more than an investment, this is a call to mission at a glocal level since some of these diseases remain largely incurable! But with three founders – all Oxford-educated neuroscientists with capabilities in molecular biology, circuit, and systems neuroscience, we see something that is worth supporting, for all nations, and all people.
Register for Tekedia Mini-MBA edition 19 (Feb 9 – May 2, 2026): big discounts for early bird.
Tekedia AI in Business Masterclass opens registrations.
Join Tekedia Capital Syndicate and co-invest in great global startups.
Register for Tekedia AI Lab: From Technical Design to Deployment (next edition begins Jan 24 2026).
To learn more, visit:
Tekedia Capital capital.tekedia.com
Exin Therapeutics www.exintherapeutics.com
---
Connect via my
LinkedIn |
Facebook |
X |
TikTok |
Instagram |
YouTube